Boston Scientific Corp. (BSX): Price and Financial Metrics
GET POWR RATINGS... FREE!
BSX POWR Grades
- Growth is the dimension where BSX ranks best; there it ranks ahead of 90.89% of US stocks.
- BSX's strongest trending metric is Stability; it's been moving up over the last 179 days.
- BSX ranks lowest in Momentum; there it ranks in the 35th percentile.
BSX Stock Summary
- BOSTON SCIENTIFIC CORP's market capitalization of $62,720,911,039 is ahead of 96.53% of US-listed equities.
- BSX's current price/earnings ratio is 105.06, which is higher than 95.49% of US stocks with positive earnings.
- In terms of volatility of its share price, BSX is more volatile than just 7.1% of stocks we're observing.
- Stocks that are quantitatively similar to BSX, based on their financial statements, market capitalization, and price volatility, are BDX, CTVA, ZTS, ETN, and ALC.
- Visit BSX's SEC page to see the company's official filings. To visit the company's web site, go to www.bostonscientific.com.
BSX Valuation Summary
- BSX's EV/EBIT ratio is 52.6; this is 511.63% higher than that of the median Healthcare stock.
- BSX's price/sales ratio has moved down 1.3 over the prior 243 months.
Below are key valuation metrics over time for BSX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BSX | 2022-11-25 | 5.0 | 3.6 | 105.9 | 52.6 |
| BSX | 2022-11-23 | 5.0 | 3.6 | 105.3 | 52.4 |
| BSX | 2022-11-22 | 5.0 | 3.5 | 104.5 | 52.0 |
| BSX | 2022-11-21 | 4.9 | 3.5 | 103.0 | 51.4 |
| BSX | 2022-11-18 | 4.9 | 3.5 | 103.1 | 51.4 |
| BSX | 2022-11-17 | 4.8 | 3.4 | 101.2 | 50.6 |
BSX Growth Metrics
- The year over year revenue growth rate now stands at 20.14%.
- The 4 year cash and equivalents growth rate now stands at 88.78%.
- The 4 year net income to common stockholders growth rate now stands at 1135.45%.
The table below shows BSX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 12,567 | 1,197 | 597 |
| 2022-06-30 | 12,329 | 1,192 | 828 |
| 2022-03-31 | 12,162 | 1,528 | 754 |
| 2021-12-31 | 11,888 | 1,870 | 985 |
| 2021-09-30 | 11,470 | 2,065 | 1,100 |
| 2021-06-30 | 11,197 | 2,243 | 526 |
BSX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BSX has a Quality Grade of C, ranking ahead of 73.14% of graded US stocks.
- BSX's asset turnover comes in at 0.362 -- ranking 120th of 186 Medical Equipment stocks.
- INGN, ECIA, and ATRC are the stocks whose asset turnover ratios are most correlated with BSX.
The table below shows BSX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.362 | 0.669 | 0.051 |
| 2021-03-31 | 0.328 | 0.649 | 0.032 |
| 2020-12-31 | 0.324 | 0.650 | 0.015 |
| 2020-09-30 | 0.331 | 0.672 | 0.003 |
| 2020-06-30 | 0.344 | 0.682 | 0.022 |
| 2020-03-31 | 0.386 | 0.704 | 0.043 |
BSX Price Target
For more insight on analysts targets of BSX, see our BSX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $51.08 | Average Broker Recommendation | 1.4 (Moderate Buy) |
BSX Stock Price Chart Interactive Chart >
BSX Price/Volume Stats
| Current price | $45.16 | 52-week high | $47.49 |
| Prev. close | $44.50 | 52-week low | $34.98 |
| Day low | $44.26 | Volume | 3,686,501 |
| Day high | $45.18 | Avg. volume | 8,019,696 |
| 50-day MA | $41.39 | Dividend yield | N/A |
| 200-day MA | $41.19 | Market Cap | 64.68B |
Boston Scientific Corp. (BSX) Company Bio
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. (Source:Wikipedia)
Latest BSX News From Around the Web
Below are the latest news stories about BOSTON SCIENTIFIC CORP that investors may wish to consider to help them evaluate BSX as an investment opportunity.
Buy-rated Boston Scientific's $615 million takeover of Apollo Endosurgery is a positive, says NeedhamBoston Scientific Corp.'s $615 million acquisition of Apollo Endosurgery Inc. announced earlier is complementary to the former's endoscopy franchise, as it leverages its gastroenterologist call point while offering the potential for it to expand into surgical endoscopy and bariatric surgery, Needham analysts aid Tuesday. The deal is expected to have no material impact on Boston Scientific's 2023 per-share earnings but to boost it after that. Needham analysts led by Mike Matson said they would wa |
Boston Scientific to acquire Apollo Endosurgery for $615 million in cashBoston Scientific Corp. said Tuesday it has agreed to acquire Apollo Endosurgery Inc. for $10 a share, or about $615 million in cash. The news sent Apollo's stock, which closed Monday at $6, up 61% in premarket trade. The company has a portfolio of devices used in endoluminal surgery procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity, and is expected to generate net sales of about $76 million in 2022. "En |
Boston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc.Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc. (Nasdaq: APEN) for a cash price of $10 per share, reflecting an enterprise value of approximately $615 million.1 |
Boston Scientific (BSX) Posts Positive Post-Market Study DataThe latest PMCF study demonstrates that Boston Scientific's (BSX) ACURATE neo2 Aortic Valve System is expected to significantly improve patient outcomes. |
Late-Breaking Post-Market Study Data Reinforce Clinical Procedural Success and Safety of the ACURATE neo2™ Aortic Valve SystemBoston Scientific Corporation (NYSE:BSX) has announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of the ACURATE neo2TM Aortic Valve System. The findings, which included a high procedural success rate of 98.4% and low rates of mortality and paravalvular leak (PVL), were presented during a late-breaking clinical trial session at PCR London Valves 2022 and published simultaneously in EuroIntervention. |
BSX Price Returns
| 1-mo | 4.76% |
| 3-mo | 10.17% |
| 6-mo | 13.15% |
| 1-year | 18.62% |
| 3-year | 4.42% |
| 5-year | 72.70% |
| YTD | 6.31% |
| 2021 | 18.16% |
| 2020 | -20.50% |
| 2019 | 27.96% |
| 2018 | 42.56% |
| 2017 | 14.61% |
Continue Researching BSX
Want to see what other sources are saying about Boston Scientific Corp's financials and stock price? Try the links below:Boston Scientific Corp (BSX) Stock Price | Nasdaq
Boston Scientific Corp (BSX) Stock Quote, History and News - Yahoo Finance
Boston Scientific Corp (BSX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...